2022
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022, 28: 923-1049. PMID: 35963508, PMCID: PMC10200071, DOI: 10.1016/j.eprac.2022.08.002.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesEvidence-based recommendationsPractice guidelinesGlycemic targetsDiabetes mellitusComprehensive careCare plansEvidence-based clinical practice recommendationsEndocrinology Clinical Practice GuidelineNew evidence-based recommendationsLiterature searchManagement of prediabetesDiabetes care teamDiabetic kidney diseaseClinical practice recommendationsComprehensive care planType 1 diabetesAmerican AssociationCare of personsHealth care professionalsSecondary diabetesBariatric surgeryInsulin therapyClinical evidenceKidney disease
2020
Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2013
Insulin pumps in children with T1DM—we told you so
Tamborlane WV, Sherr JL. Insulin pumps in children with T1DM—we told you so. Nature Reviews Endocrinology 2013, 9: 629-630. PMID: 24080733, DOI: 10.1038/nrendo.2013.190.Peer-Reviewed Original ResearchBlunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus
Arbelaez AM, Xing D, Cryer PE, Kollman C, Beck RW, Sherr J, Ruedy KJ, Tamborlane WV, Mauras N, Tsalikian E, Wilson DM, White NH, Group F. Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatric Diabetes 2013, 15: 127-134. PMID: 23992543, PMCID: PMC3858506, DOI: 10.1111/pedi.12070.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusPeak epinephrineEpinephrine responseDiabetes mellitusT1DM subjectsRecent-onset type 1 diabetes mellitusHypoglycemia-associated autonomic failureBarrier of hypoglycemiaInsulin-induced hypoglycemiaAutonomic failureCounterregulatory hormonesSubsequent hypoglycemiaGlucagon responsePatients 9Recurrent hypoglycemiaGlycemic controlHypoglycemic clampEpinephrine levelsHypoglycemiaHormonal responsesT1DMGlucagonMellitusControl 19CR responseChallenges and Future Directions of the T1D Exchange Clinic Network and Registry
Miller KM, Xing D, Tamborlane WV, Bergenstal RM, Beck RW. Challenges and Future Directions of the T1D Exchange Clinic Network and Registry. Journal Of Diabetes Science And Technology 2013, 7: 963-969. PMID: 23911177, PMCID: PMC3879760, DOI: 10.1177/193229681300700418.Peer-Reviewed Original ResearchConceptsT1D Exchange Clinic NetworkClinic registryClinic networkT1D Exchange Clinic RegistryType 1 diabetes mellitusPublic health issueElectronic health recordsDiabetes historyDiabetes mellitusDiabetes CenterMedical recordsInsulin administrationMedical conditionsWide age rangeWeb-based questionnaireRegistryAutoimmune T1DMHealth issuesHealth recordsAge rangeData extractionParticipant completionT1DMClinicLaboratory results
2012
Accuracy and Precision of the Axis-Shield Afinion Hemoglobin A1c Measurement Device
Wood JR, Kaminski BM, Kollman C, Beck RW, Hall CA, Yun JP, Cengiz E, Haller MJ, Hassan K, Klingensmith GJ, Tamborlane WV. Accuracy and Precision of the Axis-Shield Afinion Hemoglobin A1c Measurement Device. Journal Of Diabetes Science And Technology 2012, 6: 380-386. PMID: 22538150, PMCID: PMC3380782, DOI: 10.1177/193229681200600224.Peer-Reviewed Original ResearchConceptsNational Glycohemoglobin Standardization ProgramPediatric practice settingsWhole blood samplesBlood samplesHigh-performance liquid chromatographyPractice settingsDCA deviceHigher A1C levelsBoronate affinity methodMeasurement of hemoglobinA1c levelsDiabetes mellitusClinic sitesA1C resultsClinical centersAfinionCapillary bloodPatient samplesCentral laboratoryConsortium sitesA1CImmunoassay methodStandardization ProgramHPLC methodAbsolute difference
2011
A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus
Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV. A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus. Endocrine Practice 2011, 17: 862-866. PMID: 21550949, DOI: 10.4158/ep11031.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationFemaleFollow-Up StudiesGlycated HemoglobinHospitals, PediatricHospitals, UniversityHumansHypoglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulin DetemirInsulin Infusion SystemsInsulin, IsophaneInsulin, Long-ActingInsulin, Short-ActingMaleConceptsRapid-acting insulin analoguesInsulin detemirNPH insulinYounger patientsA1c levelsInitial treatmentInsulin dosesNew-onset type 1 diabetes mellitusInsulin analoguesBasal/bolus insulinTotal daily insulin dosesType 1 diabetes mellitusInsulin injection treatmentPump-treated patientsDaily insulin dosesHemoglobin A1c levelsTwice daily regimenEffective initial treatmentSevere hypoglycemic eventsNew-onset T1DMInsulin pump therapyDetemir insulinDaily regimenInsulin regimenDiabetes mellitus
2010
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal Of Medicine 2010, 363: 311-320. PMID: 20587585, DOI: 10.1056/nejmoa1002853.Peer-Reviewed Original ResearchConceptsInjection therapy groupPump-therapy groupSensor-augmented pump therapyGlycated hemoglobin levelsHemoglobin levelsType 1 diabetesPump therapyBaseline glycated hemoglobin levelMultiple daily insulin injectionsType 1 diabetes mellitusGlycated haemoglobin targetPrimary end pointProportion of patientsDaily insulin injectionsSignificant weight gainRecombinant insulin analogueHemoglobin targetsInjection therapyDiabetes mellitusSevere hypoglycemiaInsulin injectionsClinical teamInsulin analoguesEnd pointTherapy
2009
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr J, Cengiz E, Tamborlane WV. From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discovery Today 2009, 14: 973-981. PMID: 19580883, DOI: 10.1016/j.drudis.2009.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoimmunityBiosensing TechniquesBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Drug Therapy, CombinationGlycated HemoglobinHumansHypoglycemic AgentsImmunologic FactorsInfusion PumpsInsulinInsulin-Secreting CellsPancreas, ArtificialPrimary PreventionTreatment OutcomeConceptsContinuous subcutaneous insulin infusionContinuous glucose monitoringType 1 diabetes mellitusBeta-cell destructionRapid-acting insulinSubcutaneous insulin infusionTreatment of T1DMType 1 diabetesBlood glucose fluctuationsImproved insulin deliveryAutoimmune processDiabetes mellitusPediatric patientsSecondary interventionsTreatment optionsInsulin infusionNew medicationsGlucose fluctuationsGlucose monitoringInsulin deliveryArtificial pancreasPreventionTreatmentInitial studyMellitus
2008
Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes
Tamborlane W, Beck R, Bode B, Buckingham B, Chase H, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Hirsch I, Huang E, Kollman C, Kowalski A, Laffel L, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal Of Medicine 2008, 359: 1464-1476. PMID: 18779236, DOI: 10.1056/nejmoa0805017.Peer-Reviewed Original ResearchConceptsYears of ageContinuous glucose monitoringContinuous monitoring groupPatients 25 yearsGlycated hemoglobin levelsType 1 diabetesHemoglobin levelsGlucose monitoringStudy groupControl groupType 1 diabetes mellitusMulticenter clinical trialBetween-group differencesHemoglobin outcomesYounger patientsDiabetes mellitusGlycemic controlIntensive therapyPrimary outcomeSevere hypoglycemiaClinical trialsIntensive treatmentAge groupsBlood glucose metersType 1Short‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance
Burgert TS, Duran EJ, Goldberg‐Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S. Short‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatric Diabetes 2008, 9: 567-576. PMID: 18761646, DOI: 10.1111/j.1399-5448.2008.00434.x.Peer-Reviewed Original ResearchConceptsNormal glucose toleranceInsulin sensitivityGlucose toleranceObese childrenDouble-blind clinical trialType 2 diabetes mellitusSubcutaneous fatCardio-metabolic consequencesBaseline insulin sensitivityImproved insulin sensitivityInsulin-resistant adolescentsHeart rate recoveryLong-term treatmentDeep subcutaneous fatShort-term useMagnetic resonance imagingPlacebo groupCardiovascular effectsDiabetes mellitusMetS groupClinical effectsLipid parametersInsulin sensitizersInflammatory cytokinesObese adolescentsInsulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2008, 153: 547-553.e3. PMID: 18589448, DOI: 10.1016/j.jpeds.2008.04.063.Peer-Reviewed Original ResearchConceptsInsulin glargineMultiple daily injectionsMultiple daily injection regimensType 1 diabetes mellitusBaseline A1C valuesDaily insulin glargineParallel group comparisonIntermediate acting insulinIntermediate-acting insulinOccurrence of hypoglycemiaPrandial insulin lisproOverall mean changeElevated A1C.MDI regimenMDI regimensBaseline A1CInjection regimensWeek 24Adverse eventsDiabetes mellitusHemoglobin A1cPediatric patientsSevere hypoglycemiaDaily injectionsA1C values
2006
The renaissance of insulin pump treatment in childhood type 1 diabetes
Tamborlane WV, Swan K, Sikes KA, Steffen AT, Weinzimer SA. The renaissance of insulin pump treatment in childhood type 1 diabetes. Reviews In Endocrine And Metabolic Disorders 2006, 7: 205-213. PMID: 17160722, DOI: 10.1007/s11154-006-9018-9.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifePump therapyEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusChildhood type 1 diabetesRisk of hypoglycemiaInsulin pump therapyBlood sugar levelsSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenMacrovascular complicationsDiabetes mellitusPediatric patientsSevere hypoglycemiaHemoglobin levelsPatient selectionTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analoguesOptimal control of type 1 diabetes mellitus in youth receiving intensive treatment
Springer D, Dziura J, Tamborlane WV, Steffen AT, Ahern JH, Vincent M, Weinzimer SA. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. The Journal Of Pediatrics 2006, 149: 227-232. PMID: 16887440, DOI: 10.1016/j.jpeds.2006.03.052.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusRace/ethnicityLow socioeconomic statusSocioeconomic statusDiabetes mellitusLarge clinical practiceDuration of diabetesOptimal glycemic controlBody mass indexPoor metabolic controlAge 18 yearsGlycemic targetsInjection therapyGlycemic controlDiabetes controlMass indexFemale sexDatabase reviewInsulin administrationIntensive treatmentMonths durationTrial recommendationsMultiple linear regression analysisTherapeutic goalsClinical practiceFulfilling the promise of insulin pump therapy in childhood diabetes
Tamborlane WV. Fulfilling the promise of insulin pump therapy in childhood diabetes. Pediatric Diabetes 2006, 7: 4-10. PMID: 16774611, DOI: 10.1111/j.1399-543x.2006.00171.x.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoring systemContinuous subcutaneous insulin infusion (CSII) treatmentType 1 diabetes mellitusRapid-acting insulin analoguesTreatment of T1DMComplications TrialDiabetes mellitusDiabetes controlGlucose monitoring systemChildhood diabetesFavorable outcomeInsulin analoguesInfusion treatmentInsulin pumpTherapyMinimal riskT1DMDiabetesInsulinTreatmentMellitusHypoglycemiaCSIIRecent introduction
2005
Insulin Pump Treatment of Childhood Type 1 Diabetes
Weinzimer SA, Sikes KA, Steffen AT, Tamborlane WV. Insulin Pump Treatment of Childhood Type 1 Diabetes. Pediatric Clinics Of North America 2005, 52: 1677-1688. PMID: 16301088, DOI: 10.1016/j.pcl.2005.07.004.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifeLong-term microvascular complicationsEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusInsulin pump treatmentChildhood Type 1Risk of hypoglycemiaBlood sugar levelsSubcutaneous insulin infusionNew insulin analoguesTreatment of childrenMicrovascular complicationsDiabetes mellitusPump treatmentSevere hypoglycemiaHemoglobin levelsTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analoguesType 1Weight gainImpact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus
Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ. Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2005, 147: 528-534. PMID: 16227041, PMCID: PMC2258153, DOI: 10.1016/j.jpeds.2005.04.065.Peer-Reviewed Original ResearchConceptsGlucose levelsExercise nightsOvernight hypoglycemiaType 1 diabetes mellitusOvernight glycemic controlClinical Research CenterRisk of hypoglycemiaEffects of exerciseImpact of exerciseBlood glucose levelsAfternoon exerciseDiabetes mellitusGlycemic controlInsulin dosesSedentary dayExercise dayExercise sessionsDiabetes managementHypoglycemiaSeparate daysClinical sitesType 1Central laboratoryMellitusT1DMDisease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies
Weinzimer SA, Doyle EA, Tamborlane WV. Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies. Clinical Pediatrics 2005, 44: 393-403. PMID: 15965545, DOI: 10.1177/000992280504400503.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdolescentAdolescent BehaviorAdultAge FactorsAgedAttitude to HealthBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin ResistanceMaleMiddle AgedPatient CompliancePatient Education as TopicPrognosisRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsYoung diabetic patientsGlycemic controlDiabetic patientsType 1 diabetes mellitusContinuous subcutaneous insulin infusionPresence of hypoglycemiaSubcutaneous insulin infusionType 2 diabetesDisease managementContinuous glucose-monitoring systemPositive treatment outcomesGlucose-monitoring systemInsulin glargineYounger patientsDiabetes mellitusHypoglycemic episodesJuvenile patientsNocturnal hypoglycemiaInsulin infusionTreatment outcomesTreatment strategiesCareful monitoringDiabetesPatientsGlucose monitoringComparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study
Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatric Diabetes 2005, 6: 13-16. PMID: 15787896, DOI: 10.1111/j.1399-543x.2005.00088.x.Peer-Reviewed Original ResearchConceptsDCA 2000Central laboratory valuesHbA1c valuesClinical centersLaboratory valuesComplications Trial/EpidemiologyType 1 diabetes mellitusMean differenceDiabetes researchBaseline HbA1c levelsHemoglobin A1c levelsCentral laboratoryOutpatient clinical trialAdditional blood samplesCentral laboratory methodHbA1c levelsA1c levelsDiabetes mellitusDiabetes practiceDiabetes controlDiabetes InterventionsClinical trialsSame visitBlood samplesReference standardDiabetes in overweight pediatric patients
Tamborlane WV. Diabetes in overweight pediatric patients. Clinical Cornerstone 2005, 7: s25-s29. PMID: 16545735, DOI: 10.1016/s1098-3597(05)80086-9.Peer-Reviewed Original ResearchConceptsDiabetes mellitusNew-onset type 2 diabetes mellitusType 2 diabetes mellitusChildhood diabetes mellitusOverweight pediatric patientsNew diabetes casesMore effective treatmentsPediatric patientsHemoglobin levelsInadequate therapyDiabetes casesDiabetic complicationsPatient satisfactionUrine testingFamily historyEffective treatmentDM treatmentBetter outcomesMetabolic controlInsulin analoguesType 2Ethnic minority groupsHigh rateDiseasePromising new avenue